Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q2 2023 Earnings Presentation
12 slides from Adc Therapeutics Sa's earnings presentation, Aug 8, 2023
Slide 1: 2Q 2023 Earnings Call
2Q 2023 Earnings Call August 8, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Introduction 02 Kristen Harrington-Smith Commercial Highlights Chief Commercial Officer 03 Mohamed Zaki Clinical Highlights Chief Medical Officer Pepe Carmona Financial Update 04 Chief Financial Officer 3
Slide 4: Recent Highlights
Recent Highlights ▪ Net product sales: $19.2M in 2Q 2023, +11% yr/yr; volume growth of +3% qtr/qtr ZYNLONTA® ▪ New go-to-market model implemented by end of Q2 2023 to support growth (loncastuximab tesirine-lpyl) ▪ Partner Sobi completed the first EU commercial sale of ZYNLONTA in May ▪ China BLA1 fo
Slide 5: ZYNLONTA Net Sales: $19.2M in 2Q 2023, +11% yr/yr
ZYNLONTA Net Sales: $19.2M in 2Q 2023, +11% yr/yr New go-to-market model Evolving market dynamics ▪ Implemented by the end of 2Q 2023 ▪ Significant disruption during the quarter ▪ 3L+ DLBCL market remains highly fragmented with ▪ ~50% of team newly hired or in new roles no standard of care ▪ Entire
Slide 6: ZYNLONTA Ideally Suited Across Treatment Settings
ZYNLONTA Ideally Suited Across Treatment Settings Deep and durable Fast time to response single agent efficacy (median 41 days1) Manageable safety profile Simple dosing without REMS with no CRS or inpatient stay recommendations Data from EHA and ICML: At the 2-year follow-up, the median duration of
Slide 7: Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy
Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy 2L DLBCL Patient population Relapsed/refractory B-cell Non-Hodgkin Lymphoma ASCT ineligible Study summary Phase 1 trial of ZYNLONTA in combination with glofitamab, Phase 3 confirmatory trial in combination with rit
Slide 8: Prioritized Pipeline Advancing with Data in 1H 2024
Prioritized Pipeline Advancing with Data in 1H 2024 ▪ Phase 1b study exploring monotherapy treatment in patients with sarcoma and NSCLC; ADCT-601 IHC assay being finalized Targeting AXL ▪ Dose escalation progressing; maximum tolerated dose has not yet been reached ▪ Initial data from Phase 1 study e
Slide 9: 2Q 2023 Financial Update (in $ millions)
2Q 2023 Financial Update (in $ millions) Cash runway expected to extend into mid-2025 based on current business plan Balance Sheet June 30, 2023 Cash and cash equivalents $347.5 IFRS Non-IFRS (Adjusted)* Statement of Operations 2Q 2023 % vs. 2Q 2022 2Q 2023 % vs. 2Q 2022 Product Revenue, Net 19.2 +1
Slide 10: Multiple Value-Driving Catalysts Expected in 2023 and 2024
Multiple Value-Driving Catalysts Expected in 2023 and 2024 2H 2023 1H 2024 2024 ❑ ZYNLONTA: European launch by ❑ ADCT-601 (AXL): Initial data ❑ Complete enrollment of LOTIS-5 partner Sobi in 2Q 2023 from Phase 1 study study ❑ ZYNLONTA: Updated safety lead-in ❑ ADCT-901 (KAAG1): Initial data ❑ Initia
Slide 11: 2Q 2023 Earnings Call
Earnings Call 2 TH ERAPEUTICS iting Science. Inspiring Hope.
Slide 12: Reconciliation of IFRS to Non-IFRS Adjustments
Reconciliation of IFRS to Non-IFRS Adjustments in KUSD 2Q 2023 2Q 2022 Net loss (IFRS) (47,117) (64,374) Adjustments: Share-based compensation (income) expense - R&D (i) (61) 4,844 Share-based compensation (income) expense - S&M (i) (618) 1,671 Share-based compensation expense - G&A (i) 1,797 7,303